-
“After the Ice Bucket” - Neuralstem NSI-566/ALS Interview with Richard Garr
Neuralstem's President and CEO, Richard Garr, sets out the company’s progress towards its goal of creating a neural stem cell therapy that will make ALS a manageable chronic disease and give patients a normal lifespan and good quality of life in this nearly six-minute TV segment, one of four on the future of ALS research produced by BioCentury in partnership with WUSA9, the CBS affiliate in Washington, D.C. Mr. Garr gives a thorough overview of NSI-566/ALS, including the neural stem cells; specially designed surgical devices used for the world’s first intraspinal injections; “rescue, nurture and integrate” treatment benefits, and Phase I final cohort three-year results from peer-reviewed, published data. NSI-566/ALS Phase II trials concluded final surgeries in July 2014.